Integer (NYSE:ITGR – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
99.3% of Integer shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Integer and Biomerica”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integer | $1.85 billion | 2.31 | $102.81 million | $3.66 | 34.44 |
| Biomerica | $4.45 million | 1.56 | -$3.78 million | ($1.27) | -1.76 |
Integer has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Integer has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
Profitability
This table compares Integer and Biomerica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integer | 6.97% | 12.79% | 6.48% |
| Biomerica | -84.79% | -97.19% | -61.57% |
Analyst Ratings
This is a summary of current ratings for Integer and Biomerica, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integer | 0 | 13 | 1 | 0 | 2.07 |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
Integer presently has a consensus target price of $109.86, suggesting a potential downside of 12.86%. Biomerica has a consensus target price of $9.00, suggesting a potential upside of 301.79%. Given Biomerica’s higher possible upside, analysts plainly believe Biomerica is more favorable than Integer.
Summary
Integer beats Biomerica on 12 of the 14 factors compared between the two stocks.
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.
